Ovarian cancer is caused to the ovaries which is women reproductive system. Ovarian cancers start at the distal end of the fallopian tubes and spread to ovaries and the whole body in cancerous and low malignant potential cases. Lining of ovaries is made up of 3 types of cells and each type of cell can develop into different type of tumors which can be both benign and malignant. Various diagnostics tests are available for the detection of the ovarian cancers including blood test, pelvic examination, ultrasound, and several other tests such as PET scan, magnetic resonance imaging (MRI) & CT scan. Two systems are used in the staging of ovarian cancer, International Federation of Gynecology and Obstetrics system (FIGO) and American Joint Committee on Cancer (AJCC).
Increase in prevalence of ovarian cancer across the globe, rising geriatric population, and unhealthy lifestyles are some of the factors driving the global ovarian cancer market. According to the American Cancer Society, ovarian cancer ranks 5th in cancer deaths among women in the U.S. and accounts for more deaths compared to any other cancer of the women reproductive system. As per the estimates of American Cancer Society, in 2019, more than 22,530 women are expected to be diagnosed with ovarian cancer in the U.S. Along with this, surge in novel drugs adoption and ongoing research and development for treatment and diagnostic options of ovarian cancer are some of the other factors which are expected to escalate the market growth during the forecast period 2019–2026.
Increasing healthcare expenditure and rising favorable governmental policies are the factors supporting the market growth. Apart from this strong developmental pipeline of the global major players is expected to positively reinforce the ovarian cancer market. Improved chemotherapy drugs and development in the radiation therapy are the factors expected to boost the market growth.
However, lack of skilled professionals for the diagnosis of cancer and launch of the generic drugs including Gemzar, Taxol, Hycamtin, and Paraplatin are the major factors restraining the global ovarian cancer market growth. Other factor hampering the market growth is lack of awareness regarding ovarian cancer among women in the developing region.
The global ovarian cancer drugs market was valued at USD 1,246 million in 2017 and is expected to exhibit a phenomenal CAGR of 23.4% during the forecast period 2019-2026.
The global ovarian cancer market is segmented into type, treatment, end user, and region.
Based on type, the market is segmented into epithelial tumors, germ cell tumors, and stromal tumors. Amongst type, the epithelial tumors segment is expected to account for largest share of the global ovarian cancer market. High prevalence of the epithelial tumors is the key factor driving the segmental market during the forecast period 2019–2026. Germ cell tumors segment is forecasted to grow at a steady rate followed by the stromal tumors segment.
Based on treatment, the market is segregated into diagnosis, therapeutic treatment, and surgery. Diagnosis is further segmented into computed tomography (CT) scans, Ultrasound, Barium enema x-ray, Magnetic resonance imaging (MRI) scans, Chest x-ray, Positron emission tomography (PET) scan, and other diagnostic tests. Moreover, therapeutic treatment is sub segmented into chemotherapy, radiation therapy, targeted therapy, hormone therapy, and other therapeutic treatments. Amongst treatment, therapeutic treatment is expected to account for major share of the global ovarian cancer market owing to the availability of vast array of therapeutic treatment options. Diagnosis segment is anticipated to grow swiftly due to the advancements in the diagnostics sector across the globe.
Based on end user, the market is segmented into hospitals, diagnostic centers, drug stores, online pharmacies, and other end users. Amongst end users, hospitals segment is anticipated to account for major share of the market owing to the availability of advanced facilities for the treatment of ovarian cancer followed by diagnostic centers. Online pharmacies and drug stores are expected to grow at a steady rate owing to the launch of new and advanced drugs for the treatment of ovarian cancer across the globe.
In terms of region, the global ovarian cancer market is segmented into North America, Europe, Asia Pacific, and Latin America and the Middle East & Africa.
North America dominates the global ovarian cancer market owing to the constantly rising and huge geriatric population pool and advanced diagnostic centers available in the region. Demographics shift is expected to escalate the market growth in North America. According to the Population Reference Bureau, the number of geriatric population in the North America is estimated to double and reach 98 million by 2060 from 46 million in 2017. High prevalence and death rate of ovarian cancer is the other factor supporting the market growth in the region. As per the National Cancer Institute, incidence rate of ovarian cancer in the U.S. is 11.6 per 100,000 women and death rate is 7.2 per 100,000 women. Further added, in 2015 there were more than 224,940 women suffering from ovarian cancer in the U.S.
Europe is expected to account for significant share of the global ovarian cancer market. High prevalence of the ovarian cancer in the region is the key factor driving the market in the region. According to the Cancer Research UK, 7,400 new cases of the ovarian cancer were registered in the U.K every year during 2013–2015. Apart from this, ovarian cancer incidence rate in the U.K is estimated to rise by 15% during 2015–2035 and reach 32 cases per 100,000 women. Ongoing research and development regarding drugs for the treatment of ovarian cancer and presence of the major players in the region are some of the other factors supporting the market growth in Europe.
Asia Pacific is projected to grow at fastest CAGR owing to the constantly growing geriatric population and advancements in the treatment and diagnostics for the ovarian cancer.
Latin America and the Middle East & Africa is expected to account for the least share of the global ovarian cancer market owing to the Poor healthcare infrastructure coupled with low per capita income.
Some of the major players in the market are Bristol Myers Squibb Company, AstraZeneca, Genentech Inc., Eli Lilly and Company, Novogen, Inc., F. Hoffman-La Roche Ltd., GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Janssen Pharmaceuticals, Inc., Tesaro, Aetera Zenteris Inc., and Clovis Oncology.
Some of the other players with products in the late pipeline stage are Pfizer, AbbVie, ImmunoGen, Johnson & Johnson, Boehringer Ingelheim, and Oasmia Pharmaceuticals.
Research team from Griffith University in conjunction with University of Adelaide’s Research Centre for Infectious Diseases, has developed a new blood test specifically for the diagnosis of ovarian cancer. This test diagnose ovarian cancer at early stage when more treatment options are available and survival rates are better for the patient suffering from ovarian cancer.
Advancements is the diagnostic tests and subsequent ongoing research and development in treatment options is expected to escalate the market growth during the forecast period 2019–2026.
Our report covers the ovarian cancer market insights, focusing on recent developments in the market in different regions and development strategies of the companies. Moreover, following sections are specifically covered in the report.